Signet Financial Management LLC lowered its holdings in Eli Lilly and Company (NYSE:LLY – Get Rating) by 48.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,653 shares of the company’s stock after selling 10,105 shares during the period. Signet Financial Management LLC’s holdings in Eli Lilly and Company were worth $3,658,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Claro Advisors LLC grew its stake in Eli Lilly and Company by 3.0% during the first quarter. Claro Advisors LLC now owns 1,349 shares of the company’s stock valued at $463,000 after acquiring an additional 39 shares in the last quarter. Signature Wealth Management Group grew its stake in Eli Lilly and Company by 10.6% during the first quarter. Signature Wealth Management Group now owns 792 shares of the company’s stock valued at $272,000 after acquiring an additional 76 shares in the last quarter. AE Wealth Management LLC grew its stake in Eli Lilly and Company by 28.8% during the first quarter. AE Wealth Management LLC now owns 56,736 shares of the company’s stock valued at $19,484,000 after acquiring an additional 12,694 shares in the last quarter. Aprio Wealth Management LLC grew its stake in Eli Lilly and Company by 40.2% during the first quarter. Aprio Wealth Management LLC now owns 1,088 shares of the company’s stock valued at $374,000 after acquiring an additional 312 shares in the last quarter. Finally, Strong Tower Advisory Services purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $3,221,000. Institutional investors own 87.25% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the subject of a number of research reports. 3M reissued a “maintains” rating on shares of Eli Lilly and Company in a research note on Friday, April 28th. BMO Capital Markets boosted their price target on shares of Eli Lilly and Company from $430.00 to $505.00 in a research note on Thursday, May 4th. Barclays boosted their price target on shares of Eli Lilly and Company from $400.00 to $420.00 in a research note on Monday, May 1st. Cantor Fitzgerald boosted their price target on shares of Eli Lilly and Company from $432.00 to $485.00 in a research note on Friday, April 28th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $430.00 to $475.00 in a research note on Thursday, May 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $431.00.
Insiders Place Their Bets
In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $435.29, for a total value of $261,174.00. Following the sale, the chief accounting officer now owns 5,978 shares in the company, valued at $2,602,163.62. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 600 shares of the company’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $435.29, for a total value of $261,174.00. Following the sale, the chief accounting officer now owns 5,978 shares in the company, valued at $2,602,163.62. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $350.49, for a total transaction of $73,602,900.00. Following the completion of the sale, the insider now owns 102,333,810 shares in the company, valued at approximately $35,866,977,066.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,279,783 shares of company stock worth $510,549,964. 0.13% of the stock is currently owned by company insiders.
Eli Lilly and Company Trading Up 0.3 %
Shares of NYSE LLY traded up $1.16 during midday trading on Friday, hitting $458.84. 4,832,135 shares of the company traded hands, compared to its average volume of 2,266,886. Eli Lilly and Company has a 12-month low of $296.32 and a 12-month high of $462.26. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.02 and a current ratio of 1.30. The stock has a 50-day moving average price of $425.58 and a 200 day moving…
Read More: Signet Financial Management LLC Sells 10,105 Shares of Eli Lilly and Company